Computer assisted prediction of absorption, distribution, metabolism, excretion and toxicity (ADMET) was performed using the SwissADME online tool, for the dihydroxyfumaric acid (DFH4) and its synthesized derivatives, which showed good antiradical activities in previous studies (Fig. 1). The colored part of the radar shows the desired physico-chemical surface suitable for oral bioavailability of the compound: LIPO (lipofilicity): -0,7 < XLOGP3 < +5,0; SIZE: 150g/mol < molecular weight < 500g/mol; POLAR (polarity): 20Å2 < TPSA < 130Å2; INSOLU (insolubility): -6 < log S (ESOL) < 0; INSATU (insaturation): 0.25 < ration of sp3 C atoms < 1; FLEX (flexibility): 0 < number of rotatable bonds < 9. All studied compounds satisfy Lipiski’s rule of five, and have a good estimated bioavailability (0.56), while Fig.1. also shows a good drug-likeness. a) DFH4 b) dimethyl 2,3- dihidroxifumarate c) (E)-methyl 2,3-dihydroxy-4-oxo-4-(phenylamino)but- 2-enoate d) 2,3-dihydroxy-N1,N4- di(pyridin-2- il)fumaramide e) (E)-3-(1H-benzo [d]imidazol-2-il)- 2,3- dihydroxiacrylic acid (a) (E)-1,2-di(1H-benzo [d]imidazol-2-il)etene-1,2- diol Fig.1. Bioavailability radars for the studied compounds.